Previous 10 | Next 10 |
—Satish Chandran of Lays Sciences and Physis Pharma, Inc. to join Board of Directors as Steve Barbarick transitions to advisory role— FORT COLLINS, Colo., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or ...
The IPO market's run of small issuers continued this past week with two healthcare micro caps, joined by five SPACs. The pipeline was fairly active with initial filings from three IPOs and two SPACs. Meihua International Medical Technologies downsized and priced at the midpoint to rai...
Medical device maker Marizyme (OTCQB:MRZM) is seeking to uplist its shares to Nasdaq and conduct a public offering of around $15M. The maker of grafting treatments for use in coronary bypass surgery said in a filing that it plans to offer 3M shares in the range of $4 to $6. Underwriters will ...
Jupiter, FL - ( NewMediaWire ) - January 05, 2022 - Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s DuraGraft rel...
JUPITER, Fla., Dec. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc . (“ Marizyme ” or the “ Company ”) ( OTCQB:MRZM ), is pleased to announce the closing of its acquisition of My Health Logic Inc., a subsidiary of Health Log...
JUPITER, FL - ( NewMediaWire ) - December 03, 2021 - Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and diagnose diseases of unmet clinical need announced today that results of the GOAL Study (Vienna Heart ...
Jupiter, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to prevent, treat and diagnose diseases of unmet clinical need, announced today that it h...
The development-stage biotech company, Marizyme (OTCQB:MRZM +12.8%), has named David Barthel as its new chief executive officer. The appointment comes more than seven months after the company disclosed the resignation of former CEO Neil Campbell. Mr. Barthel most recently led Health...
JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc . (“ Marizyme ” or the “ Company ”) ( OTCQB:MRZM ), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme. In hi...
Marizyme, Inc. Issues Letter to Shareholders PR Newswire JUPITER, Fla. , March 31, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue ...
News, Short Squeeze, Breakout and More Instantly...
JUPITER, FL - ( NewMediaWire ) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft ® will no longer require refrigerated storage and will be able to be stored at controlled room temperatures of 20 o C-25 o C allowing it to be ...
JUPITER, FL - ( NewMediaWire ) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to advance the commercial...
--News Direct-- Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for...